Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CNTB
CNTB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CNTB News
CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART SHOWS GOOD TOLERABILITY AND SAFETY SIMILAR TO PLACEBO
1d ago
moomoo
CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART SHOWS QUICK AND LONG-LASTING EFFECTIVENESS IN PHASE 3 STUDY FOR ATOPIC DERMATITIS OVER 52 WEEKS
1d ago
moomoo
CONNECT Biopharma Reports Encouraging Preliminary Results from Phase 1 Trial of Intravenous Rademikibart in Asthma and COPD Patients
1d ago
moomoo
Connect Biopharma Secures $20.2 Million in Private Placement
1d ago
Newsfilter
Connect Biopharma Reports Positive Clinical Data and Funding
23h ago
NASDAQ.COM
Connect Biopharma Reports Positive Phase 1 Results for Rademikibart
1d ago
NASDAQ.COM
Rademikibart Phase 3 Trial Shows Promising Efficacy and Safety Results
1d ago
Newsfilter
Atopic Dermatitis Market Growth Insights
Feb 16 2026
Newsfilter
Plus Therapeutics Prices Public Offering, Raising $15 Million
Jan 15 2026
NASDAQ.COM
BTIG Affirms Buy Rating for Connect Biopharma Holdings, Keeps $10 Price Target Intact
Nov 13 2025
Benzinga
Connect Biopharma Announces Financial Results for Q3 2025 and Offers Business Update
Nov 12 2025
Newsfilter
Immuneering Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Friday
Oct 31 2025
Benzinga
BTIG Begins Coverage of Connect Biopharma Holdings with a Buy Rating and Sets Price Target at $10
Oct 31 2025
Benzinga
Connect Biopharma to Participate in Two Investor Conferences This September
Aug 27 2025
Newsfilter
What Makes Connect Biopharma Holdings Limited Sponsored ADR (CNTB) a Strong Momentum Stock: Buy Now?
Jul 30 2025
NASDAQ.COM
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
Jul 22 2025
Newsfilter
Show More News
